225 Actinium PSMA-617

N/A

Report date: 2026/05/22 14:09:20
NME

Base Information

Drug Name225 Actinium PSMA-617
Drug Alias Name225 Actinium PSMA-617225Ac-PSMA 617AAA 817225Ac-PSMA-617
ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Actinium > 225Ac +[5] 
Mechanisms of ActionProstate-Specific Membrane Antigen inhibitorsPositron-emission tomography enhancersIonising radiation emitters
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeTaiwan +[17] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNovartis Pharma AgEndocyte IncAdvanced Accelerator Applications Sa
China Registration ClassN/A

Develop Information

Active CompaniesSofie CoNovartis Pharma AgEndocyte Inc +[5] 
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A